Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Kindred Biosciences Inc's Business Segments
Kindred Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 4
Regions Reported
-
Kindred Biosciences Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Asset Sale60.8%
- Manufacturing32.1%
- Royalty7.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Asset Sale | $ 2 | 60.8% |
| Manufacturing | $ 1 | 32.1% |
| Royalty | $ 0 | 7.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Kindred Biosciences Inc
Kindred Biosciences Inc. is a biopharmaceutical company based in San Francisco, California. The company specializes in the development of innovative therapeutics for both human and animal health. It was founded in 2012 by Dr. Richard Chin, who previously served in executive positions at several successful biopharmaceutical companies.
Kindred Biosciences focuses on identifying and advancing drug candidates that address unmet medical needs in veterinary medicine. The company uses its proprietary science and technology platforms to develop safe and effective therapies for pets, often employing a similar approach to human drug development. The ultimate goal is to improve the health and well-being of companion animals while also generating value for stakeholders.
The company's research and development efforts span across various therapeutic areas, including dermatology, internal medicine, oncology, and biologics. Kindred Biosciences has a robust pipeline of product candidates at different stages of development. These candidates address a range of diseases and conditions, such as allergic dermatitis, obesity, osteoarthritis, atopic dermatitis, gastritis, and immune-mediated diseases.
Kindred Biosciences takes a rigorous approach to drug development, adhering to standards set by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company conducts preclinical and clinical trials to assess the safety, efficacy, and pharmacokinetics of its drug candidates. It also conducts post-approval studies to gather additional data and monitor the long-term effects of its therapies.
In addition to its internal development efforts, Kindred Biosciences actively seeks partnerships and collaborations with other industry leaders to maximize the potential of its technology platforms and expand its product portfolio. The company has established collaborations with academic institutions, research organizations, and other biopharmaceutical companies.
Beyond drug development, Kindred Biosciences is dedicated to building a strong and sustainable business. The company has a commercial team that focuses on the marketing, distribution, and sales of its approved products. It also pursues strategic acquisitions and licensing deals to enhance its capabilities and broaden its market reach.
As a socially responsible organization, Kindred Biosciences values corporate citizenship and environmental stewardship. The company strives to operate in an ethical and environmentally conscious manner, adhering to all applicable regulations and guidelines. It also actively engages with the veterinary community, pet owners, and advocacy groups to promote responsible pet ownership and educate about the importance of veterinary medicine.
Overall, Kindred Biosciences is a cutting-edge biopharmaceutical company dedicated to improving the health and quality of life for companion animals. With a robust pipeline of product candidates and a commitment to innovation, the company is well-positioned to make a significant impact in the field of veterinary medicine.
Kindred Biosciences focuses on identifying and advancing drug candidates that address unmet medical needs in veterinary medicine. The company uses its proprietary science and technology platforms to develop safe and effective therapies for pets, often employing a similar approach to human drug development. The ultimate goal is to improve the health and well-being of companion animals while also generating value for stakeholders.
The company's research and development efforts span across various therapeutic areas, including dermatology, internal medicine, oncology, and biologics. Kindred Biosciences has a robust pipeline of product candidates at different stages of development. These candidates address a range of diseases and conditions, such as allergic dermatitis, obesity, osteoarthritis, atopic dermatitis, gastritis, and immune-mediated diseases.
Kindred Biosciences takes a rigorous approach to drug development, adhering to standards set by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company conducts preclinical and clinical trials to assess the safety, efficacy, and pharmacokinetics of its drug candidates. It also conducts post-approval studies to gather additional data and monitor the long-term effects of its therapies.
In addition to its internal development efforts, Kindred Biosciences actively seeks partnerships and collaborations with other industry leaders to maximize the potential of its technology platforms and expand its product portfolio. The company has established collaborations with academic institutions, research organizations, and other biopharmaceutical companies.
Beyond drug development, Kindred Biosciences is dedicated to building a strong and sustainable business. The company has a commercial team that focuses on the marketing, distribution, and sales of its approved products. It also pursues strategic acquisitions and licensing deals to enhance its capabilities and broaden its market reach.
As a socially responsible organization, Kindred Biosciences values corporate citizenship and environmental stewardship. The company strives to operate in an ethical and environmentally conscious manner, adhering to all applicable regulations and guidelines. It also actively engages with the veterinary community, pet owners, and advocacy groups to promote responsible pet ownership and educate about the importance of veterinary medicine.
Overall, Kindred Biosciences is a cutting-edge biopharmaceutical company dedicated to improving the health and quality of life for companion animals. With a robust pipeline of product candidates and a commitment to innovation, the company is well-positioned to make a significant impact in the field of veterinary medicine.
Kindred Biosciences, Inc. a biotechnology company, focuses on developing and commercializing innovative biopharmaceuticals for companion animals. Their primary segments revolve around the development of animal health products, particularly for pets such as dogs and cats. Here is an extensive description of the companys segments, products, and services:
Segments
1. Therapeutics for Companion Animals:
This segment concentrates on creating treatments for various diseases and conditions affecting pets. The main focus areas include:
- Oncology: Development of treatments for various types of cancers found in pets, leveraging monoclonal antibodies and other biologic drugs.
- Immunology: Products aimed at managing allergic diseases and immune system disorders in animals.
2. Biologics Development:
Kindred Biosciences specializes in biologics, which are products derived from biological sources. This includes:
- Monoclonal Antibodies: Targeted therapies designed to bind to specific antigens in order to treat diseases, including autoimmune disorders in pets.
- Protein-based Therapies: Innovations that utilize proteins to enhance healing processes or reduce inflammation.
3. Research and Development (R&D):
Continuous investment in R&D to discover new treatment options and improve existing products. This encompasses:
- Preclinical and Clinical Studies: Extensive testing phases to ensure the safety and efficacy of new therapies before they reach the market.
- Collaborations and Partnerships: Working with universities, research institutions, and other companies to advance veterinary medicine.
Products
1. Monoclonal Antibodies:
Kindred Biosciences has developed several monoclonal antibody products targeting conditions like:
- Atopic Dermatitis: Treatments designed to alleviate symptoms of this common allergic skin condition in dogs and cats.
- Cancer therapies: Products targeting specific cancer cells in pets, providing alternatives to traditional chemotherapy.
2. Enzyme-based Products:
These products aid in various metabolic processes within pets, enhancing their overall health and aiding in recovery from illness.
3. Vaccines:
Vaccination products aimed at preventing common infectious diseases in companion animals, thereby protecting their health and well-being.
4. Topical and Injectable Formulations:
These include formulations designed for easy administration for various treatments, ensuring compliance and effectiveness in managing diseases across different species of companion animals.
Services
1. Clinical Trials and Support:
Providing comprehensive clinical trial services ranging from initial design to execution, analysis, and regulatory submission. Services include:
- Site Management: Collaboration with veterinary clinics and hospitals to facilitate trials.
- Data Management: Collection, analysis, and reporting of trial data to ensure compliance with regulatory standards.
2. Consultation for Veterinarians:
Offering support to veterinarians through educational resources on new treatments, product usage, and best practices for managing conditions in pets.
3. Regulatory Affairs:
Expertise in navigating the regulatory landscape for veterinary products, ensuring that all products meet government and industry standards before reaching the market.
4. Veterinary Educational Programs:
Programs designed to educate veterinary professionals on the latest developments in animal health care, new products, and innovative treatment protocols.
In summary, Kindred Biosciences, Inc. plays a crucial role in advancing veterinary medicine through an extensive range of products and services designed to address the various health needs of companion animals. Their commitment to innovation in therapeutics, particularly through the application of biologics and monoclonal antibodies, positions them as a significant contributor to the animal health sector.
Segments
1. Therapeutics for Companion Animals:
This segment concentrates on creating treatments for various diseases and conditions affecting pets. The main focus areas include:
- Oncology: Development of treatments for various types of cancers found in pets, leveraging monoclonal antibodies and other biologic drugs.
- Immunology: Products aimed at managing allergic diseases and immune system disorders in animals.
2. Biologics Development:
Kindred Biosciences specializes in biologics, which are products derived from biological sources. This includes:
- Monoclonal Antibodies: Targeted therapies designed to bind to specific antigens in order to treat diseases, including autoimmune disorders in pets.
- Protein-based Therapies: Innovations that utilize proteins to enhance healing processes or reduce inflammation.
3. Research and Development (R&D):
Continuous investment in R&D to discover new treatment options and improve existing products. This encompasses:
- Preclinical and Clinical Studies: Extensive testing phases to ensure the safety and efficacy of new therapies before they reach the market.
- Collaborations and Partnerships: Working with universities, research institutions, and other companies to advance veterinary medicine.
Products
1. Monoclonal Antibodies:
Kindred Biosciences has developed several monoclonal antibody products targeting conditions like:
- Atopic Dermatitis: Treatments designed to alleviate symptoms of this common allergic skin condition in dogs and cats.
- Cancer therapies: Products targeting specific cancer cells in pets, providing alternatives to traditional chemotherapy.
2. Enzyme-based Products:
These products aid in various metabolic processes within pets, enhancing their overall health and aiding in recovery from illness.
3. Vaccines:
Vaccination products aimed at preventing common infectious diseases in companion animals, thereby protecting their health and well-being.
4. Topical and Injectable Formulations:
These include formulations designed for easy administration for various treatments, ensuring compliance and effectiveness in managing diseases across different species of companion animals.
Services
1. Clinical Trials and Support:
Providing comprehensive clinical trial services ranging from initial design to execution, analysis, and regulatory submission. Services include:
- Site Management: Collaboration with veterinary clinics and hospitals to facilitate trials.
- Data Management: Collection, analysis, and reporting of trial data to ensure compliance with regulatory standards.
2. Consultation for Veterinarians:
Offering support to veterinarians through educational resources on new treatments, product usage, and best practices for managing conditions in pets.
3. Regulatory Affairs:
Expertise in navigating the regulatory landscape for veterinary products, ensuring that all products meet government and industry standards before reaching the market.
4. Veterinary Educational Programs:
Programs designed to educate veterinary professionals on the latest developments in animal health care, new products, and innovative treatment protocols.
In summary, Kindred Biosciences, Inc. plays a crucial role in advancing veterinary medicine through an extensive range of products and services designed to address the various health needs of companion animals. Their commitment to innovation in therapeutics, particularly through the application of biologics and monoclonal antibodies, positions them as a significant contributor to the animal health sector.